Vafadar‐Afshar G, Rasmi Y, Yaghmaei P, et al. - Researchers run this 3-month study to determine how nanocurcumin administration could impact cytokines levels among hemodialysis patients. Participants were 54 hemodialysis cases randomized to either nanocurcumin or placebo. Experts used enzyme‐linked immunosorbent assay and real‐time polymerase chain reaction, to assess serum concentrations and gene expressions of tumor necrosis factor‐alpha (TNF‐α) and interleukin 6 (IL‐6). A decrease in both serum levels and gene expression of IL‐6 and TNF‐α was shown to be induced by nanocurcumin supplementation in hemodialysis patients. Further inquiry is warranted for the feasibility as well as potential clinical advantages of nanocurcumin treatment to decrease inflammation in hemodialysis patients.